The earnings transcript for Amgen's second quarter 2012 financial results presents several key points that could influence the stock price in the short term:

1. **Strong Financial Performance**: Amgen reported solid revenue and earnings per share growth, driven by the performance of established and newly launched products. This strong financial performance is likely to be positively received by investors[1].

2. **Pipeline Progress**: The company highlighted significant advancements in its R&D pipeline, including promising data on PCSK9 and sclerostin antibodies, which could drive future growth and excitement among investors[1].

3. **Guidance Update**: Amgen raised its 2012 guidance for revenues and earnings per share, indicating confidence in its business momentum. This update is generally positive for the stock[1].

4. **Operational Efficiency**: The company emphasized its commitment to maintaining operating expenses at or below revenue growth, which suggests efficient management and potential for continued profitability[1].

5. **Commercial Performance**: The execution of commercial strategies for key products like Enbrel, Prolia, and XGEVA was highlighted as successful, contributing to the overall positive outlook[1].

Given these points, the short-term impact on Amgen's stock price is likely to be positive due to the strong financial performance, promising pipeline advancements, and updated guidance.

**Rating: 1**